- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05026242
Effects of Almond Consumption on Innate and Adaptive Immune System (AlmondIS)
Effects of Almond Consumption on Innate Myeloid and Lymphoid Cells Composition and Activity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the last months, with the whole world grappling with COVID-19 and because like in many other diseases, the host immune system determines the progress of COVID-19 and the severity, there is a frantic race for finding treatment strategies based on current knowledge until effective vaccine is developed. Therefore, the modulation of inflammatory response and cytokine production using immunonutrition makes more sense than ever.
The almond is a tree nut, rich in fiber, vitamin E, biotin, minerals such as magnesium and phytonutrients, specifically flavonoids, plant sterols, phenolic acids and could have a potential beneficial role in immune system. However, beyond its beneficial role and down-lowering specific circulating cytokines in low-grade chronic inflammatory diseases, the role of almond on both innate and adaptive immune system has not been explored.
The investigators hypothesize that regular consumption of almonds will contribute to strengthening the immune system through the modulation of specific circulating miRNAs.
The primary objective is to evaluate the effect of almond consumption on the maturation of innate lymphoid cells (ILCs).
Secondarily, the insvestigators aims to:
Examine the effect of regular consumption of almonds in the context of a Western-style diet on: a) innate immune system through the analysis of other blood cell populations including monocytes and lymphocyte's subsets (T-cells, B-cells). b) adaptive immune system assessed by: b.1) circulating inflammatory markers and b.2) ex-vivo ability for peripheral blood mononuclear cell (PBMC) to produce cytokines.
c) circulating miRNAs, focusing in immune-related miRNAs.
- To investigate whether changes in miRNAs mediate the effect of almonds on ILCs activity and the other innate and adaptive immune system indicators analysed.
The expected results would enhance understanding of the role of almonds in immune function, to establish the basis of new research for the promotion of the health benefits of nuts in immune-related diseases and facilitate the use of personalized nutrition to improve human health.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Monica Bullo, PhD
- Phone Number: +34977759388
- Email: monica.bullo@urv.cat
Study Locations
-
-
Tarragona
-
Reus, Tarragona, Spain, 43201
- IISPV
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI 25.0-34.9 Kg/m2
- Western-style diet
- Unhealthy snacks other than nuts (i.e. potato chips, crackers, corn puffs, pretzels, pastries, cookies, candies) >1 serving/day
Exclusion Criteria:
- Regular smokers (≥ 10 cigarettes/day)
- Diagnoses of type 2 diabetes
- Cardiovascular disease, chronic kidney disease, liver disease, active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption, cancer - active malignant cancer or history of malignancy within the last 5 years, psychiatric disorders
- Use of anti-inflammatory or antioxidants drugs
- Not stable medication in the last 3 months
- Regular alcohol consumption above of the national recommendations or drug abuse
- Frequent consumption of nuts
- Allergy to the intervention products or other severe allergies and food intolerances
- Dietary patterns interfering with the study protocol (e.g. vegetarian, vegan, low carbohydrate dieters, high fat dieters) two months prior inclusion, during the study or plans to initiate during the study
- Daily use of multivitamin or mineral supplements
- Bad dentures, implying difficulty to chew nut
- Pregnancy or lactation, pregnancy within the past 12 month or plans to become pregnant during the study
- Consumption of probiotics or prebiotics in the last 3 months and laxatives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Almond intervention
Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
|
Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
|
Active Comparator: Control
Participants will be provided with isocaloric snacks
|
Participants will be provided with isocaloric snacks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in innate myeloid and lymphoid cells
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
CD45+, CD103+, CD56+, CD14+,CD16+, CD8+, CD19+, CD4+, CD3+, CD36+, CD44+, ROR γ t, NKp46+, FoxP3+ will be assessed by means of flow cytometry in cryopreserved cells.
|
These outcomes will be assessed at baseline and at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in lymphocyte subsets
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
Lymphocyte subsets will be measured using Ficoll-Paque (GE Healthcare) density gradient centrifugation and flow cytometry.
Results will be expressed in 10 (9)/L cells
|
These outcomes will be assessed at baseline and at 8 weeks
|
Changes in immune cells activity assessed by citokyne production
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
Innate lymphoid and myeloid cells activity will be assessed in cryopreserved PBMCs.
Inflammation mediators ( such as hs-CRP, IL1, IL2, IL4, IL-6, IL-7, IL-10, TNFα, IFN-γ, TGF-β, TLR4, NOD1) will be assessed with chemical assays (ELISA).
Results will be expressed as mass/volume
|
These outcomes will be assessed at baseline and at 8 weeks
|
Changes in immune cells activity assessed by adaptor molecules
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
A study of the molecular signaling using Western blot qauntification of adaptor molecules that play a pivotal role in immune cell activation through Toll-like receptors and therefore are good markers for specific immune cells activities
|
These outcomes will be assessed at baseline and at 8 weeks
|
Changes in inflammatory markers and related molecules in plasma/serum
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
Several citokynes related immune cells (i.e TNF, IL6, IL1) and other circulating inflmmatory markers (i.e.
CRP, amiloid) will be measured by ELISA related methods.
Results will be expressed in mass/volume
|
These outcomes will be assessed at baseline and at 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in circulating miRNAs
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
20 circulating miRNA will be measured using TaqMan MicroRNA Assays.
Results will be expressed as relative increase or decrease
|
These outcomes will be assessed at baseline and at 8 weeks
|
Changes in gut microbiota composition
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
16S RNA will be sequenced and functional in silico analyses using existing datasets will be conducted.
Data will be expressed in relative abundace (OTUS/ASV) at genus, family and/or specie level
|
These outcomes will be assessed at baseline and at 8 weeks
|
Changes in gut microbiota function
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
Fecal targeted quantitative metabolomic multi-platform analyses will be conducted to identify changes in fecal metabolites related to the intervention (different metabolites including lipid species, aminoacids, bile acids, short-chain fatty acids...will be included)
|
These outcomes will be assessed at baseline and at 8 weeks
|
Changes in circulating metabolites concentrations
Time Frame: These outcomes will be assessed at baseline and at 8 weeks
|
We will use a multi-platform targeted/untargeted approach to identify/quantify metabolites related to the intervention and outcomes.
(different metabolites including lipid species, aminoacids, bile acids, short-chain fatty acids...will be included)
|
These outcomes will be assessed at baseline and at 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Monica Bullo, Prof, Pere Virgili
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IH-21-BULLOM-NR-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune System
-
University of HelsinkiTampere UniversityCompletedImmune System DisordersFinland
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteers)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
SanofiTerminatedImmune System DisorderUnited States, Spain
-
Shanghai Henlius BiotechCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...CompletedGraft vs Host Disease | Immune System DisordersUnited States
-
Universitätsklinikum Hamburg-EppendorfRecruitingPregnancy | Immune System DisorderGermany
-
University of New MexicoRecruitingDNA Damage | Immune System DisorderUnited States
Clinical Trials on Almond intervention
-
Diabetes Foundation, IndiaAlmond Board of California; National Diabetes Obesity and Cholesterol FoundationRecruiting
-
Diabetes Foundation, IndiaCompleted
-
Oregon State UniversityRecruitingInflammation | Metabolic Syndrome | DysbiosisUnited States
-
University of California, DavisCompletedWrinkleUnited States
-
Almond Board of CaliforniaKGK Science Inc.CompletedHypercholesterolemia | HDL-CCanada
-
Taipei Medical UniversityCompleted
-
Columbia UniversityAlmond Board of CaliforniaCompletedObesity | Overweight | Fatty Liver | Metabolic Syndrome XUnited States
-
San Diego State UniversityActive, not recruiting
-
University of California, Los AngelesAlmond Board of CaliforniaCompletedSkin LaxityUnited States